☆ 4.1 Article

Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated (hATTR) amyloidosis : Results from the phase 3 APOLLO study

REVUE NEUROLOGIQUE (2018)

Get Full Text
Add to Collection

Journal

REVUE NEUROLOGIQUE
Volume 174, Issue -, Pages S37

Publisher

Elsevier BV
DOI: 10.1016/j.neurol.2018.01.085

Keywords

-

Categories

Clinical Neurology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.